Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

Tissue antigens - 1 Jan 2010

Lalonde R G, Thomas R, Rachlis A, Gill M J, Roger M, Angel J B, Smith G, Higgins N, Trottier B

Abstract excerpt

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination antiretroviral therapy in HIV-infected patients. It is currently recommended as a preferred or an alternative NRTI in antiretroviral-naïve patients. The major toxicity of abacavir is a hypersensitivity reaction (HSR), which occurs in approximately 5% of treated patients. There is a strong association between the human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Canada
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to HLA-B Antigens

Share to Randomized Controlled Trials as Topic

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 19843279
DOI: 10.1111/j.1399-0039.2009.01383.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.PMID 19843279Read ↗

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.Semantic proximity Read ↗

HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Successful translation of pharmacogenetics into the clinic: the abacavir example.Semantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

HLA-B*5701 testing to predict abacavir hypersensitivitySemantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Current trends in screening across ethnicities for hypersensitivity to abacavir.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Semantic proximity Read ↗

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.